2023
Abatacept-Prophylaxis Based Haploidentical Transplantation May Allow Sustained Engraftment and Offset Gvhd in Non-Malignant Disorders
Ngwube A, Shah N, Schulz G, Krishnamurti L, Shenoy S. Abatacept-Prophylaxis Based Haploidentical Transplantation May Allow Sustained Engraftment and Offset Gvhd in Non-Malignant Disorders. Blood 2023, 142: 4901. DOI: 10.1182/blood-2023-191145.Peer-Reviewed Original ResearchNon-malignant disordersPost-transplant cyclophosphamideSickle cell diseaseGVHD prophylaxisHematopoietic transplantationEvaluable patientsHaploidentical transplantationImmune suppressionBone marrowFirst year post-HCTGrade 1 acute GVHDChronic GVHD riskChronic skin GVHDGVHD-free survivalPost-transplant lymphoproliferationsRadiation-containing regimensYear post-HCTPhase 2 trialReduced intensity conditioningSerious infectious complicationsSystemic immune suppressionT-cell chimerismAllogeneic hematopoietic transplantationPrimary outcome measureStem cell boost
2019
Administration of BPX-501 Cells Following Αβ T and B-Cell-Depleted HLA Haploidentical HSCT (haplo-HSCT) in Children with Acute Leukemias (AL)
Galaverna F, Ruggeri A, Merli P, Kapoor N, Agarwal-Hashmi R, Aquino V, Jacobsohn D, Qasim W, Nemecek E, Krishnamurti L, Manwani D, Kuhn M, Locatelli F, Naik S. Administration of BPX-501 Cells Following Αβ T and B-Cell-Depleted HLA Haploidentical HSCT (haplo-HSCT) in Children with Acute Leukemias (AL). Transplantation And Cellular Therapy 2019, 25: s15-s16. DOI: 10.1016/j.bbmt.2018.12.082.Peer-Reviewed Original ResearchSteroid-resistant GVHDAcute leukemiaEvaluable ptsEfficacy outcomesΑβ TT cellsB cellsPediatric ptsBetter overall clinical responsePost-transplant GvHD prophylaxisHigh-risk acute leukemiaHLA-haploidentical HSCTOverall clinical responseSubset of ptsPrimary graft failureTumor-specific immunityHost disease symptomsInducible caspase-9 safety switchAllogeneic HSCTEnhanced graftGVHD prophylaxisHaplo-HSCTHaploidentical HSCTLeukemic effectsPlatelet engraftment
2016
A trial of unrelated donor marrow transplantation for children with severe sickle cell disease
Shenoy S, Eapen M, Panepinto J, Logan B, Wu J, Abraham A, Brochstein J, Chaudhury S, Godder K, Haight A, Kasow K, Leung K, Andreansky M, Bhatia M, Dalal J, Haines H, Jaroscak J, Lazarus H, Levine J, Krishnamurti L, Margolis D, Megason G, Yu L, Pulsipher M, Gersten I, DiFronzo N, Horowitz M, Walters M, Kamani N. A trial of unrelated donor marrow transplantation for children with severe sickle cell disease. Blood 2016, 128: 2561-2567. PMID: 27625358, PMCID: PMC5123194, DOI: 10.1182/blood-2016-05-715870.Peer-Reviewed Original ResearchConceptsEvent-free survivalIncidence rateAcute chest syndrome episodesPosterior reversible encephalopathy syndromeSevere sickle cell diseaseUnrelated donor marrow transplantationVaso-occlusive pain crisesAllogeneic bone marrow transplantEffective GVHD prophylaxisGVHD-related deathsHost disease (GVHD) prophylaxisShort-course methotrexateReversible encephalopathy syndromeUnrelated donor transplantsPhase 2 trialBone marrow transplantTranscranial Doppler velocitiesSickle cell diseaseAcute GVHDChronic GVHDEFS ratesEncephalopathy syndromeGVHD prophylaxisTransplant indicationConditioning regimen
2005
Matched Sibling Donor Hematopoietic Cell Transplantation for Sickle Cell Disease Using a Reduced Intensity Conditioning Regimen Can Lead To Stable Long Term Engraftment.
Krishnamurti L, Wu C, Baker K, Wagner J. Matched Sibling Donor Hematopoietic Cell Transplantation for Sickle Cell Disease Using a Reduced Intensity Conditioning Regimen Can Lead To Stable Long Term Engraftment. Blood 2005, 106: 3172. DOI: 10.1182/blood.v106.11.3172.3172.Peer-Reviewed Original ResearchHematopoietic cell transplantationSickle cell diseaseDaily x 5 daysIntensity conditioning regimenCell diseaseConditioning regimenDay 100Stable long-term engraftmentLong-term engraftmentRIC regimenClinical characteristicsCell transplantationDay 180Term engraftmentHigh-risk sickle cell diseaseDonor hematopoietic cell transplantationLineage-specific chimerism analysisPeripheral blood genomic DNARegimen-Related ToxicitiesAnti-thymocyte globulinGroup of patientsChronic graftDonor erythropoiesisGVHD prophylaxisHost disease